The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
- PMID: 32879427
- PMCID: PMC7467142
- DOI: 10.1038/s41375-020-01038-8
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
Conflict of interest statement
The authors declare that they have no conflict of interest.
Comment on
-
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.Leukemia. 2020 Jul;34(7):1805-1815. doi: 10.1038/s41375-020-0891-0. Epub 2020 Jun 9. Leukemia. 2020. PMID: 32518419 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials